Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Eggermont

Showing results (31-40 of 171) with videos related to

Pageof 18
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1990
Solitary malignant Schwannoma: clinical aspects, immunohistochemistry and ultrastructureK P de Jong, V D Vuzevski, A M Eggermont, et al.
NMR in Biomedicine|August 1, 1995
31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusionP E Sijens, A M Eggermont, P V van Dijk, et al.
European Journal of Clinical Investigation|December 1, 1996
Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancerT C Stam, M Jongen-Lavrencic, A M Eggermont, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Effects of the interferon-inducer ABPP on colon cancer in rats; importance of tumor load and tumor siteA M Eggermont, R L Marquet, R W de Bruin, et al.
Head & Neck|September 1, 1993
Therapeutic lymphadenectomy in melanomas of the head and neckW Van de Vrie, A M Eggermont, W L Van Putten, et al.
Cancer Treatment Reports|February 1, 1985
Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatmentA M Eggermont, W Weimar, R L Marquet, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the ratW Van de Vrie, A M Jonker, R L Marquet, et al.
The Cancer Journal From Scientific American|February 11, 1998
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative GroupU Keilholz, G Stoter, C J Punt, et al.
Seminars in Surgical Oncology|April 21, 1998
Isolated limb perfusion in primary and recurrent melanoma: indications and resultsD Liénard, A M Eggermont, B B Kroon, et al.
Journal of the National Cancer Institute|November 1, 1987
Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cellsA M Eggermont, E P Steller, R T Ottow, et al.
Pageof 18

Showing results (31-40 of 171) with videos related to

Sort By:
Pageof 18
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1990
Solitary malignant Schwannoma: clinical aspects, immunohistochemistry and ultrastructureK P de Jong, V D Vuzevski, A M Eggermont, et al.
NMR in Biomedicine|August 1, 1995
31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusionP E Sijens, A M Eggermont, P V van Dijk, et al.
European Journal of Clinical Investigation|December 1, 1996
Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancerT C Stam, M Jongen-Lavrencic, A M Eggermont, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Effects of the interferon-inducer ABPP on colon cancer in rats; importance of tumor load and tumor siteA M Eggermont, R L Marquet, R W de Bruin, et al.
Head & Neck|September 1, 1993
Therapeutic lymphadenectomy in melanomas of the head and neckW Van de Vrie, A M Eggermont, W L Van Putten, et al.
Cancer Treatment Reports|February 1, 1985
Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatmentA M Eggermont, W Weimar, R L Marquet, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the ratW Van de Vrie, A M Jonker, R L Marquet, et al.
The Cancer Journal From Scientific American|February 11, 1998
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative GroupU Keilholz, G Stoter, C J Punt, et al.
Seminars in Surgical Oncology|April 21, 1998
Isolated limb perfusion in primary and recurrent melanoma: indications and resultsD Liénard, A M Eggermont, B B Kroon, et al.
Journal of the National Cancer Institute|November 1, 1987
Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cellsA M Eggermont, E P Steller, R T Ottow, et al.
Pageof 18